Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104783 | 1.00 | KMT2A (0.43) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL8295426 | 0.88 | MAPT (0.45) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL8297703 | 0.87 | NPC1 (0.44) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL8295420 | 0.84 | ALDH1A1 (0.52) | KMT2AMEN1HSD17B10KDM4CSMN1; SMN2 | |
| SCHEMBL19796232 | 0.83 | KMT2A (0.42) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL23835297 | 0.83 | MEN1 (0.44) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL26100338 | 0.82 | CNR2 (0.48) | NPC1RAB9AOPRK1 | |
| SCHEMBL19304000 | 0.82 | NPC1 (0.46) | KMT2AMEN1NPC1RAB9AKDM4C | |
| SCHEMBL8295423 | 0.82 | MEN1 (0.47) | KMT2AMEN1CREBBPNPC1RAB9A | |
| SCHEMBL22031112 | 0.81 | MEN1 (0.42) | KMT2AMEN1CREBBPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268903-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4422746-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423058-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077040-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268903-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | KMT2A 3583/4885MEN1 2822/4885CREBBP 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.